These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29234909)

  • 61. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin.
    Brasileiro A; Fonseca Oliveira J; Pinheiro S; Paiva-Lopes MJ
    Lupus; 2016 May; 25(6):663-5. PubMed ID: 26846694
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
    Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
    Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The rarity of antinuclear antibody negativity in systemic lupus erythematosus: comment on the article by Merrill et al.
    Major GA
    Arthritis Rheum; 2011 Apr; 63(4):1157-8; author reply 1158. PubMed ID: 21452333
    [No Abstract]   [Full Text] [Related]  

  • 64. Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.
    So MW; Koo BS; Kim YJ; Kim YG; Lee CK; Yoo B
    Mod Rheumatol; 2014 Sep; 24(5):855-7. PubMed ID: 24517558
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Childhood hermolytic uremic syndrome associated with systemic lupus erythematosus.
    Wu CY; Su YT; Wang JS; Chiou YH
    Lupus; 2007; 16(12):1006-10. PubMed ID: 18042599
    [No Abstract]   [Full Text] [Related]  

  • 66. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
    Hu C; Lu L; Wan JP; Wen C
    Curr Med Chem; 2017; 24(20):2241-2249. PubMed ID: 28302011
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.
    Humrich JY; von Spee-Mayer C; Siegert E; Alexander T; Hiepe F; Radbruch A; Burmester GR; Riemekasten G
    Ann Rheum Dis; 2015 Apr; 74(4):791-2. PubMed ID: 25609413
    [No Abstract]   [Full Text] [Related]  

  • 68. [Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
    Harten P
    Med Klin (Munich); 2003 Jun; 98(6):344; author reply 344-5. PubMed ID: 12877108
    [No Abstract]   [Full Text] [Related]  

  • 69. [Chorea, lupus and antiphospholipid antibodies].
    Reiner P; Piette JC; Leroux G; Vidailhet M; Costedoat-Chalumeau N
    Rev Med Interne; 2012 Apr; 33(4):206-8. PubMed ID: 22365472
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.
    Ramos-Casals M; Díaz-Lagares C; Khamashta MA
    Arthritis Rheum; 2009 Sep; 61(9):1281-2. PubMed ID: 19714598
    [No Abstract]   [Full Text] [Related]  

  • 71. Abatacept for the treatment of systemic lupus erythematosus.
    Pimentel-Quiroz VR; Ugarte-Gil MF; Alarcón GS
    Expert Opin Investig Drugs; 2016; 25(4):493-9. PubMed ID: 26878310
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.
    Dooley MA; Ginzler EM
    Rheum Dis Clin North Am; 2006 Feb; 32(1):91-102, ix. PubMed ID: 16504823
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus.
    Limal N; Cacoub P; Sène D; Guichard I; Piette JC
    Lupus; 2008 Jan; 17(1):69-71. PubMed ID: 18089688
    [No Abstract]   [Full Text] [Related]  

  • 74. Myocarditis successfully treated with intravenous immunoglobulin in a patient with systemic lupus erythematous and myositis.
    Barnado A; Kamen DL
    Am J Med Sci; 2014 Mar; 347(3):256-7. PubMed ID: 24521767
    [No Abstract]   [Full Text] [Related]  

  • 75. Central variant of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: new associations?
    Bag AK; Curé JK; Sullivan JC; Roberson GH
    Lupus; 2010 Feb; 19(2):225-6. PubMed ID: 19880556
    [No Abstract]   [Full Text] [Related]  

  • 76. Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.
    Zhang H; Chambers W; Sciascia S; Cuadrado MJ
    Expert Rev Clin Pharmacol; 2016; 9(5):681-94. PubMed ID: 26907827
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Photoprotective properties of chloroquine phosphate.
    Wozniacka A; Lesiak A; McCauliffe DP; Sysa-Jedrzejowska A
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1133-4. PubMed ID: 17714153
    [No Abstract]   [Full Text] [Related]  

  • 78. Systemic lupus erythematosus.
    Rahman A; Isenberg DA
    N Engl J Med; 2008 Feb; 358(9):929-39. PubMed ID: 18305268
    [No Abstract]   [Full Text] [Related]  

  • 79. Acute onset myopia as a presenting feature of systemic lupus erythematosus.
    Kamath YS; Singh A; Bhat SS; Sripathi H
    J Postgrad Med; 2013; 59(3):245-6. PubMed ID: 24029214
    [No Abstract]   [Full Text] [Related]  

  • 80. Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.
    Wang Y; Zhou W; Zhang Z
    Rheumatology (Oxford); 2015 Jan; 54(1):194-5. PubMed ID: 25288787
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.